Experience

Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. as a minority…

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with a series of refinancing transactions that are intended to improve liquidity, extend debt maturities and enable…

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which Valeant issued new debt to refinance its shorter term…

Davis Polk advised McKesson Corporation in connection with the offering of $1 billion aggregate principal amount of notes issued by Change Healthcare Holdings, LLC and Change Healthcare…

Davis Polk advised the administrative agent in connection with a $200 million delayed draw term loan facility for Magellan Pharmacy Services, Inc., a wholly owned subsidiary of…

Davis Polk is advising Aetna Inc. in connection with the sale by Aetna and Humana Inc. of certain of their respective Medicare Advantage assets to Molina Healthcare, Inc. for a total…

Davis Polk advised the administrative agent in connection with a $200 million term loan facility (the “Credit Facility”) for Magellan Pharmacy Services, Inc., a wholly owned subsidiary of…

Davis Polk advised McKesson Corporation on its creation of a new health care information technology company, which will combine substantially all of Change Healthcare Holdings, Inc.’s…

Davis Polk is advising Verisk Analytics, Inc. in connection with the $820 million sale of Verisk’s health care services business, Verisk Health, to Veritas Capital. The transaction,…

Davis Polk is advising Charles River Laboratories International, Inc. on its acquisition of WIL Research for approximately $585 million. The transaction, which is expected to close early in…